Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study

被引：0

作者：

Eyre, Toby ^{[1
]}

Pagel, John M. ^{[2
]}

Coombs, Catherine C. ^{[3
]}

Shah, Nirav N. ^{[4
]}

Lamanna, Nicole ^{[5
]}

Lech-Maranda, Ewa ^{[6
]}

Woyach, Jennifer ^{[7
]}

Wierda, William G. ^{[8
]}

Cheah, Chan Y. ^{[9
,10
]}

Roeker, Lindsey ^{[11
]}

Patel, Manish R. ^{[12
]}

Fakhri, Bita ^{[13
]}

Barve, Minal A. ^{[14
]}

Tam, Constantine S. ^{[15
,16
]}

Lewis, David ^{[17
]}

Gerson, James N. ^{[18
]}

Alencar, Alvaro ^{[19
]}

Taylor, Justin ^{[19
]}

Abedel-Wahab, Omar ^{[11
]}

Ghia, Paolo ^{[20
,21
]}

Schuster, Stephen J. ^{[18
]}

Chen, Jessica ^{[22
]}

Nair, Binoj ^{[23
]}

Tsai, Donald E. ^{[23
]}

Ku, Nora C. ^{[23
]}

Davids, Matthew S. ^{[24
,25
]}

Brown, Jennifer R. ^{[24
,25
]}

Jurczak, Wojciech ^{[26
]}

Mato, Anthony R. ^{[11
]}

机构：

[1] Oxford Univ Hosp NHS Fdn Trust, Churchill Canc Ctr, Oxford, England

[2] Swedish Canc Inst, Seattle, WA USA

[3] Univ North Carolina Chapel Hill, Chapel Hill, NC USA

[4] Med Coll Wisconsin, Brookfield, WI USA

[5] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA

[6] Inst Hematol & Transfus Med, Krakow, Poland

[7] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[9] Linear Clin Res, Perth, WA, Australia

[10] Sir Charles Gairdner Hosp, Perth, WA, Australia

[11] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[12] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

[13] Univ Calif San Francisco, San Francisco, CA 94143 USA

[14] Mary Crowley Canc Res, Dallas, TX USA

[15] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[16] Univ Melbourne, Melbourne, Vic, Australia

[17] Derriford Hosp, Plymouth Hosp NHS Trust, Plymouth, Devon, England

[18] Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA

[19] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[20] Univ Vita Salute San Raffaele, Milan, Italy

[21] IRCCS Osped San Raffaele, Milan, Italy

[22] Eli Lilly & Co, Indianapolis, IN 46285 USA

[23] Loxo Oncol Lilly, Stamford, CT USA

[24] Dana Farber Canc Inst, Boston, MA 02115 USA

[25] Harvard Med Sch, Boston, MA 02115 USA

[26] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 193卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH2021-OR

引用

页码：37 / 38

页数：2

共 50 条

[31] Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton's Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation
Thompson, Meghan C.
Coombs, Catherine C.
Roeker, Lindsey E.
Jensen, Jeffrey L.
Shah, Nirav N.
Luo, Thomas
Patel, Krish
Bailey, Neil
Fakhri, Bita
Eyre, Toby A.
Ghione, Paola
Rhodes, Joanna M.
Zelenetz, Andrew D.
Taylor, Justin
Palomba, Maria Lia
Meyer, Kendall
Rao, Danielle
Fox, Yehudit
Aronson, Julia H.
Court, Sarah
Abdel-Wahab, Omar
Mato, Anthony R.
BLOOD, 2022, 140 : 9885 - 9888
[32] Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study
Byrd, J. C.
Blum, K. A.
Burger, J. A.
Coutre, S. E.
Sharman, J. P.
Furman, R. R.
Flinn, I. W.
Grant, B. W.
Richards, D. A.
Zhao, W.
Heerema, N. A.
Johnson, A. J.
Izumi, R.
Hamdy, A.
O'Brien, S. M.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[33] Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
Rhodes, Joanna M.
Mato, Anthony R.
DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 919 - 926
[34] PHASE 1 STUDY OF SINGLE AGENT CC-292, A HIGHLY SELECTIVE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Brown, J. R.
Harb, W. A.
Hill, B. T.
Gabrilove, J.
Sharman, J. P.
Schreeder, M. T.
Barr, P. M.
Foran, J. M.
Miller, T. P.
Burger, J. A.
Kelly, K. R.
Mahadevan, D.
Ma, S.
Barnett, E.
Marine, J.
Nava-Parada, P.
Azaryan, A.
Mei, J.
Kipps, T. J.
HAEMATOLOGICA, 2014, 99 : 54 - 55
[35] Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
Brown, Jennifer R.
Harb, Wael A.
Hill, Brian T.
Gabrilove, Janice
Sharman, Jeff P.
Schreeder, Marshall T.
Barr, Paul M.
Foran, James M.
Miller, Thomas P.
Burger, Jan A.
Kelly, Kevin R.
Mahadevan, Daruka
Ma, Shuo
Li, Yan
Pierce, Daniel W.
Barnett, Evelyn
Marine, Jeffrey
Miranda, Monika
Azaryan, Ada
Yu, Xujie
Nava-Parada, Pilar
Mei, Jay
Kipps, Thomas J.
HAEMATOLOGICA, 2016, 101 (07) : 295 - 298
[36] A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study
Song, Yuqin
Cai, Qingqing
Jiang, Ming
Zhang, Lei
Sun, Xiuhua
Jin, Zhengming
Li, Lanfang
Jing, Hongmei
Peng, Zhigang
Yang, Haiyan
Qi, Junyuan
Zhou, Hui
Yang, Wei
Zhou, Min
Ji, Chunyan
Xu, Wei
Ding, Kaiyang
Yu, Li
Wang, Zheng
Liu, Nawei
Lou, Yejiang
Shen, Yue
Chen, Yi
Tan, Fenlai
Zhu, Jun
BLOOD, 2023, 142
[37] BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Eyre, Toby A.
Thompson, Phillip
Wierda, William G.
Simkovic, Martin
Grosicki, Sebastian
Jurczak, Wojciech
Wang, Yucai
Mocikova, Heidi
Zinzani, Pier Luigi
Tam, Constantine Si Lun
Davids, Matthew Steven
Chang, Amy E.
Oliveira, Joana M.
Lu, Yi
Leow, Ching Ching
Roeker, Lindsey Elizabeth
Woyach, Jennifer Ann
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[38] Treatment With the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Results From a Phase 1/2 Trial
Awan, Farrukh T.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 10 - 11
[39] Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Jain, Nitin
D'Olimpio, James
Gillis-Smith, Andew
Lee, Seung Tae
Shah, Nirav N.
Pinilla-Ibarz, Javier
Coombs, Catherine C.
Barrientos, Jacqueline C.
Ma, Shuo
Sawa, Masaaki
Miyamoto, Kyoko
Arimura, Akinori
Gandhi, Varsha
Wierda, William G.
BLOOD, 2023, 142
[40] BRUIN CLL-322: a phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Leow, Ching Ching
Eyre, Toby A.
Thompson, Phillip
Wierda, William
Simkovic, Martin
Grosicki, Sebastian
Jurczak, Wojciech
Wang, Yucai
Mocikova, Heidi
Zinzani, Pier Luigi
Tam, Constantine S.
Davids, Matthew
Chang, Amy E.
Oliveira, Joana M.
Lu, Yi
Roeker, Lindsey
Woyach, Jennifer
LEUKEMIA & LYMPHOMA, 2023, 64 : S77 - S77

← 1 2 3 4 5 →